ACP
ROIV icon

Altitude Crest Partners’s Roivant Sciences ROIV Stock Holding History

Altitude Crest Partners’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-454,766
Closed -$4.79M – 22
2024
Q1 		$4.79M Sell
454,766
-353,295
-44% -$3.81M 2.05% 18
2023
Q4 		$9.07M Buy
+808,061
New +$7.88M 6.07% 7

Other funds holding ROIV

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PSC
Patient Square Capital Menlo Park, California $564M AUM 261.3% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

Altitude Crest Partners's ROIV Position: Q2 2024 in Review

Altitude Crest Partners sold out of Roivant Sciences (ROIV) in Q2 2024, closing a stake of 454,766 shares — an estimated $4.79M sold.

Altitude Crest Partners first reported a position in ROIV in Q4 2023 and held it in 2 quarters. The position peaked at $9.07M in Q4 2023. 293 funds tracked by Wall St. Rank hold ROIV as of Q2 2024.

  • Altitude Crest Partners reported no remaining Roivant Sciences position as of Q2 2024 after selling out during the quarter.
  • Altitude Crest Partners sold 454,766 Roivant Sciences shares in Q2 2024, an estimated $4.79M.
  • Altitude Crest Partners first reported a position in Roivant Sciences in Q4 2023 and held it in 2 quarters.
  • Altitude Crest Partners's Roivant Sciences position peaked at $9.07M in Q4 2023.
  • 293 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2024.

Based on Altitude Crest Partners's 13F filing for Q2 2024.